Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 32 | ECE2013 | Next issue

15th European Congress of Endocrinology

Poster Presentations

Bone and Osteoporosis

ea0032p70 | Bone and Osteoporosis | ECE2013

Bone loss in inflammation-mediated osteoporosis: a role for the P2×7 receptor?

Kvist Torben , Petersen Solveig , Frederiksen Anja , Syberg Susanne , Jorgensen Niklas , Schwarz Peter

Bone loss in chronic autoimmune inflammatory diseases is a major clinical problem. Inflammation-mediated osteoposis (IMO) is the first animal model of generalized osteoporosis resulting from inflammation. The P2×7 receptor, an ATP-gated ion-channel, is primarily expressed on immune and bone cells. ATP is now seen as a novel inflammatory mediator, with P2×7 as main target of the pro-inflammatory activity. The P2×7-receptor has a regulatory role in bone formation ...

ea0032p71 | Bone and Osteoporosis | ECE2013

Abstract withdrawn....

ea0032p72 | Bone and Osteoporosis | ECE2013

Circadian rhythm of circulating sclerostin in healthy young men

Shankarnarayan Santosh H , Ahluwalia Rupa , Hamilton Amanda , Barraclough Dong L , Fraser William D , Vora Jiten P

Introduction: It is recognised that osteocytes, by secreting sclerostin plays a more central role in bone homeostasis. Sclerostin is a physiological inhibitor of bone formation. By binding to the LRP5/6 receptor sclerostin inhibits the Wnt signalling pathway. A cross-sectional study was undertaken to ascertain whether an endogenous sclerostin circadian rhythm exists in healthy individuals.Subjects and methods: Six healthy young men with normal BMD were a...

ea0032p73 | Bone and Osteoporosis | ECE2013

Cross-correlation of circulating sclerostin over 24 h to PTH, phosphate and bone markers in healthy young men

Shankarnarayan Santosh H , Ahluwalia Rupa , Hamilton Amanda , Barraclough Dong Liu , Fraser William D , Vora Jiten P

Introduction: Osteotropic hormones demonstrate circadian rhythms which are integral to bone homeostasis. Sclerostin is a physiological inhibitor of bone formation. We have established that Sclerostin has a distinct circadian rhythm with a nocturnal peak. Analysis was performed to determine the relationship of Sclerostin levels to PTH, Calcium, Phosphate, βCTX and P1NP in healthy young men.Methods: Six healthy young men with normal BMD were admitted ...

ea0032p74 | Bone and Osteoporosis | ECE2013

Bone quality, as measured by trabecular bone score (TBS), in patients with primary hyperparathyroidism

Eller-Vainicher Cristina , Filopanti Marcello , Palmieri Serena , Ulivieri Fabio Massimo , Morelli Valentina , Zhukouskaya Volha V. , Cairoli Elisa , Pino Rosa , Naccarato Antonella , Verga Uberta , Scillitani Alfredo , Beck-Peccoz Paolo , Chiodini Iacopo

The fracture risk in primary hyperparathyroidism (PHPT) is partially independent of bone mineral density (BMD) and seems to depend on decreased bone quality, which is still reliably assessed only with invasive techniques. Trabecular bone score (TBS) is a grey-level texture measurement acquired during a dual X-ray absorptiometry (DXA) lumbar spine scan and it has been recently proposed as index of bone quality. This study is aimed to assess the role of TBS in predictin...

ea0032p75 | Bone and Osteoporosis | ECE2013

Calcium homeostasis in women with non-metastatic breast cancer with osteoporosis after a single-dose of denosumab: a pilot study

Mandanas Stylianos , Toulis Konstantinos , Mathiopoulou Lemonia , Margaritidou Efterpi , Georgopoulos Konstantinos , Boudina Maria , Chrisoulidou Alexandra , Pazaitou-Panayiotou Kalliopi

Introduction: Women with non-metastatic breast cancer form a distinct subpopulation in which calcium homeostasis in response to treatment with denosumab has not been extensively investigated.Methods: Female patients with osteoporosis, who were eligible for treatment with denosumab, were prospectively enrolled (2011–2012) and divided into two groups; Group A consisting of patients with either no history or benign diseases non affecting bone metabolis...

ea0032p76 | Bone and Osteoporosis | ECE2013

Long-term prospective evaluation of the effects of estroprogestagen therapy on the bone mineral density of girls with Turner syndrome carrying various PvuII AND XbaI polymorphisms of ER-α

Sowinska-Przepiera Elzbieta , Andrysiak-Mamos Elzbieta , Jarzabek-Bielecka Grazyna , Syrenicz Justyna , Chelstowski Kornel , Syrenicz Anhelli

Introduction: Reduced bone mineral density (BMD) is present in many women with Turner syndrome (TS), while hypo-estrogenism is known to play a vital role in bone mineralization disturbances. It has been suggested that genetic factors play an important role in the regulation of BMD. The aim of this study was to analyze the association between PvuII and XbaI ER-a polymorphisms and BMD in TS patients subjected to estroprogestagen (EP) treatment.Material and...

ea0032p77 | Bone and Osteoporosis | ECE2013

Cathepsin K secretion in human primary osteoblastic cell cultures and its influence by different glucose concentrations

Goia-Socol Monica , Duncea Ileana , Goia-Socol Mihai-Andrei , Hazi Georgeta , Leucuta Daniel-Corneliu , Tomoaie Gheorghe , Suteu Mihai , Georgescu Carmen Emanuela

One of the causes of secondary osteoporosis is type 1 DM (1DM), an autoimmune disease where insulin replacement is mandatory for controlling blood sugar levels. Among the mechanisms involved in osteoporosis in 1DM is increased bone resorption, mainly osteoclasts being responsible for this process. However, osteoblasts also seem to have an active contribution by secreting products with resorptive properties, one of these being cysteine protease Cathepsin K, as mentioned by a fe...

ea0032p78 | Bone and Osteoporosis | ECE2013

Effects of Denosumab treatment on insulin resistance in postmenopausal women with osteoporosis

Tzioras Konstantinos , Mizamtsidi Maria , Chronaiou Aikaterini , Vasiliou Georgia , Tagara Sofia , Vryonidou Andromachi

Introduction: Denosumab is a new pharmacotherapy option for postmenopausal osteoporosis. It is a human monoclonal antibody against RANKL, acting as an osteoprotegerin (OPG) analog. Recently, osteoprotegerin levels were found to be elevated in type two diabetes while insulin resistance was shown to be positively associated with decreased serum OPG levels, in healthy obese subjects. However, no study has been conducted in order to clarify the effect of anti-RANKL factors adminis...

ea0032p79 | Bone and Osteoporosis | ECE2013

Impact of the FRAX® tool and the NOGG guidelines on the indication of bone mineral density in Spanish postmenopausal women

Kyriakos Georgios , Casariego Alfonso Vidal , Turcios Dalia Avila , Moreno Ana Hernandez , Fernandez Alicia Calleja , Suarez Ma Dolores Blanco , Taibo Rocio Villar , Pomar Maria D. Ballesteros , Rodriguez Isidoro Cano

Introduction: The National Osteoporosis Guideline Group (NOGG) recommends determine BMD in patients who present an intermediate risk of osteoporotic fracture using the FRAX® tool, follow-up for low risk, and treatment for high risk. In 2011, 3163 BMD were performed in the Complejo Asistencial Universitario de León (CAULE). Since the cost for each BMD is 58.6* (BOCYL 31/01/2011), annual spending could rise to *185 352. The aim was to assess whether fracture risk calcu...

ea0032p80 | Bone and Osteoporosis | ECE2013

Increased IL17A serum levels associated with low estrogen levels can play a role in postmenopausal osteoporosis

Molnar Ildiko , Bohaty Ilona , Somogyine-Vari Eva

Postmenopausal osteoporosis is characterized by lower bone mass, loss of structural integrity, and sometimes becomes life-threatening. The development of postmeno-pausal osteoporosis is multifactorial. Estrogen plays a preventing role in the bone resorption inhibiting the secretion of proinflammatory IL1 and TNFα cytokines. IL17 proinflammatory citokine is a new candidate in the pathogenesis of osteoporosis. IL17 levels are increased in estrogen deficiency.<p class="a...

ea0032p81 | Bone and Osteoporosis | ECE2013

Effects of the tamoxifen on calcitonin producing thyroid C cells and bone in rat model of male osteoporosis

Filipovic Branko , Pantelic Jasmina , Manojlovic-Stojanoski Milica , Trifunovic Svetlana , Nestorovic Natasa , Persinic-Popovska Florina , Jurjevic Branka sosic

Thyroid C cells produce bioregulatory peptid calcitonin (CT), which lowers plasma calcium (Ca) and acts as an inhibitor of bone resorption. In this study we investigated the effects of tamoxifen, as a selective estrogen receptor modulator on thyroid C cells and skeletal changes in middle-aged orchidectomized (Orx) rats as an animal model of male osteoporosis. Fifteen-month-old male Wistar rats were divided into Orx and a sham-operated (SO) groups. Two weeks after gonadectomy, ...

ea0032p82 | Bone and Osteoporosis | ECE2013

The value of PRP/PRF in the treatment of bisphosphonates-induced maxillary osteonecrosis: preliminary study

Costan Victor-Vlad , Ciofu Mihai Liviu , Popescu Eugenia , Vulpoi Carmen

Background: Intravenous bisphosphonates treatment brings real benefits to patients with bone metastases. Unfortunately, this treatment sometimes has a difficult to treat complication, often disabling for the patients – the osteonecrosis of the jaws. A new approach in the management of this complication is the use of platelet rich plasma (PRP).Patients and methods: Five patients aged between 62 and 72 years old (three men and two women) were included...

ea0032p83 | Bone and Osteoporosis | ECE2013

Bone mineral density in patients with hypersomatotropism

Shepelkevich Alla , Stopchenskaya Anastasiya , Bilodid Irina , Lobashova Veronika , Salko Olha , Vasilieva Natalia

Background and aim: Hypersomatotropism is known to be associated with musculoskeletal disorders, particularly, osteoporosis and increased fracture rates. However controversial data about the effects of acromegaly on bone mineral density (BMD) have been published. The aim of our research was to evaluate bone mineral density (BMD) in patients with hypersomatotropism.Materials and methods: The study included 66 patients (20 men, 44 women) with hypersomatotr...

ea0032p84 | Bone and Osteoporosis | ECE2013

Effects of treatment for acromegaly on bone mineral density: is pegvisomant protective on lumbar BMD?

Brigante Giulia , Santi Daniele , Diazzi Chiara , De Vincentis Sara , Ferrannini Giulia , Madeo Bruno , Carani Cesare , Simoni Manuela , Rochira Vincenzo

Background: GH–IGF1 status is important for bone health. Acromegaly affects bone status, but less is known on the role of treatments for acromegaly on bone mineral density (BMD). Pegvisomant (Peg) is effective in treating acromegaly by reducing IGF1. As serum GH is not influenced by Peg, it is not known if residual, direct GH effects on bone (not IGF1 mediated) are preserved during treatment.Methods: To evaluate the effects of Peg on BMD, we compare...

ea0032p85 | Bone and Osteoporosis | ECE2013

HLA class I, Cw*01 and Cw*15 alleles can play a preventing role in serum IL17 elevation associated with postmenopausal osteoporosis in Hungary

Bohaty Ilona , Jurasne-Lukovics Monika , Somogyine-Vari Eva , Kozma Laszlo , Danko Katalin , Molnar Ildiko

IL17 proinflammatory cytokine through T cell activation has prominent bone-wasting effect. Our previous results highlighted the role of IL17 in postmenopausal osteoporosis. To demonstrate the HLA allele association with the increased IL17 levels in postmenopausal osteoporosis was the object of the study.HLA class I and II alleles were measured in 64 postmenopausal women (in four subgroups: with low IL17 (1, 3) and high (>3.04 pmol/l) IL17 levels (2, ...

ea0032p86 | Bone and Osteoporosis | ECE2013

Bone health in type 1 diabetes patients with celiac disease

Kota Sunil Kumar , Meher Lalit Kumar , Modi Kirtikumar D , Jammula Sruti

Objectives: Type one diabetes mellitus (T1DM) is associated with various autoimmune conditions including celiac disease. Both these conditions are independently and variably associated with risk of osteoporosis. The current study intended to study bone health parameters and factors affecting it in patients with T1DM with serological evidence of celiac disease (CD).Methods: A cross sectional study including 100 type one diabetes patients following up in o...

ea0032p87 | Bone and Osteoporosis | ECE2013

Oxidative stress in middle age males with osteoporosis: correlation of hormonal pattern and plasma total antioxidant capacity

Raimondo Sebastiano , Tamburrelli Francesco Ciro , Di Segni Chantal , Persano Mariasara , Festa Roberto , Silvestrini Andrea , Meucci Elisabetta , Pontecorvi Alfredo , Mancini Antonio

Male idiopathic osteoporosis is an underestimated disease, despite its clinical and social importance. The biochemical mechanisms are still poorly understood even if the interaction between genetic factors and hormone environment (especially gonadal steroids and GH) plays a undoubtful role. In previous studies we demonstrated low plasma total antioxidant capacity (TAC) in hypogonadal patients. The aim of this study was to investigate oxidative stress as risk factor for bone fr...

ea0032p88 | Bone and Osteoporosis | ECE2013

Lean body mass and leptin, but not fat mass are independent predictors of bone mass in postmenopausal women

Constantinescu Georgiana , Novac Roxana , Gaspar Ioana , Preda Cristina , Vulpoi Carmen , Mogos Voichita , Branisteanu Dumitru D

Body weight is positively correlated to bone mass. While gravity represents a stimulation stress for bone turnover, endocrine function of adipocytes may also influence bone.Objectives: We investigated the relative influence of weight, body composition and leptin upon lumbar bone mass in pre and postmenopausal women.Materials and methods: Cross-sectional study including six groups varying from 8 to 15 pre- / postmenopausal healthy v...

ea0032p89 | Bone and Osteoporosis | ECE2013

Association of the (TTTA)n repeat polymorphism of CYP19 gene with bone mineral density in Greek peri- and postmenopausal women

Markatseli Anastasia , Lazaros Leandros , Kostoulas Harilaos , Sakaloglou Prodromos , Markoula Sofia , Tigas Stelios , Georgiou Ioannis , Tsatsoulis Agathocles

Introduction: Aromatase is encoded by the CYP19 gene and catalyzes the conversion of androgens to estrogens, which in turn regulate skeletal homeostasis. Polymorphisms in the CYP19 gene have been studied for their association with bone mineral density (BMD) in the general population with mixed results.Objectives: To explore the influence of the CYP19 (TTTA)n repeat polymorphism on BMD and serum levels of osteoprotegerin (OPG), receptor activator...

ea0032p90 | Bone and Osteoporosis | ECE2013

Vitamin D receptor polymorphisms and bone mass indices in post menarcheal indian adolescent girls

Kota Sunil Kumar , Meher Lalit Kumar , Jammula Sruti , Modi Kirtikumar D

Objective: The aim of the present study was to assess the association between vitamin D receptor (VDR) gene polymorphism and bone mass indices in Indian adolescent girls.Methods: The current study was a cross sectional one including 100 post menarcheal girls aged 15–18 years. Serum levels of ionized calcium, inorganic phosphorus, alkaline phosphatase, parathyroid hormone and 25 hydroxy vitamin D were measured. Bone mineral content (BMC), Bone area (...

ea0032p91 | Bone and Osteoporosis | ECE2013

Bone health in children with GH deficiency

Kota Sunil Kumar , Meher Lalit Kumar , Jammula Sruti , Modi Kirtikumar D

Objectives: The current study intended to assess the impact of GH deficiency (GHD) on bone health after using various size corrections.Methods: Thirty prepubescent children with GHD (male:female=20:10, mean age −9.4±3.5 years) were included in the study. Data on anthropometry and total body bone mineral content (TBBMC), bone area (TBBA) and lean body mass (TBLBM) by dual energy X-ray absorptiometry were collected. Anthropometric Z-sco...

ea0032p92 | Bone and Osteoporosis | ECE2013

The effect of monthly Ibandronate on bone mineral density and bone turnover markers in patients with hemophilia A or B and increased risk for fracture

Anagnostis Panagiotis , Vyzantiadis Tomoleon-Achilleas , Charizopoulou Maria , Adamidou Fotini , Karras Spyridon , Slavakis Arisitidis , Garipidou Vasilia , Vakalopoulou Sofia

Introduction: Haemophilia A and B has been associated with increased prevalence of low bone mineral density (BMD). However, no study has so far evaluated the effects of anti-osteoporotic therapy on BMD.Methods/design: The primary endpoint of this prospective study was to estimate the effect of 12-month therapy of oral ibandronate 150 mg/month on BMD in patients with haemophilia A and B. Secondary endpoint was its effect on bone turnover markers (BTM), in...

ea0032p93 | Bone and Osteoporosis | ECE2013

Age overlooked as a risk factors for osteoporosis

Andersen Stig , Nielsen Ole , Laurberg Peter

Osteoporosis is a debilitating condition that can be prevented by timely detection and treatment. Detection requires referral for dual energy X-ray absorptiometry (DXA) that depends on risk factors. We estimated the importance of risk factors for a T-score of <−2.5 measured by spine and hip DXA in all men and women referred from general practice for a DXA scan at Aalborg University Hospital during a 3 years period. Risk factors were assessed by questionnaire...

ea0032p94 | Bone and Osteoporosis | ECE2013

Trabecular bone score and bone mineral density in Ukrainian normal women depending on duration of postmenopausal period

Povoroznyuk Vladyslav , Dzerovych Nataliia

Aim: The aim of this study is evaluating trabecular bone score (TBS) and bone mineral density (BMD) in normal women depending on duration of postmenopausal period (PMP).Materials and methods: We’ve examined 122 normal women aged 40–79 years (mean age – 56.2±0.8 years; mean height – 162.6±0.5 cm; mean weight – 71.5±1.3 kg), who were divided into the groups depending on duration of PMP: without menopause (with normal...

ea0032p95 | Bone and Osteoporosis | ECE2013

Bone metabolism with special emphasis to osteoprotegerin and vitamin D3 concentrations in premenopausal women with thyroid dysfunction

Tuchendler Dominika , Tuchendler Renata , Skorkowska-Telichowska Katarzyna , Bolanowski Marek

Objectives: The objective was to evaluate effects of hyperthyroidism and hypothyroidism on bone metabolism in premenopausal women with special emphasis to osteoprotegerin (OPG) and vitamin D3 (vD).Materials and methods: A total of 119 women aged 18–52 years were studied (38 with recently diagnosed hyperthyroidism; 40 with newly diagnosed hypothyroidism; 41 healthy women as controls). Patients were followed up for a period of 1 year. BMD, ...

ea0032p96 | Bone and Osteoporosis | ECE2013

Efficacy and safety of monthly oral minodronate for the treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients

Hirano Fuminori , Takeda Yasutaka , Saito Hiroki , Matsumoto Kakuya , Nishimura Hideo

Rheumatoid arthritis (RA) is a chronic inflammatory disease that results in generalized bone loss and increased fracture risk. Although glucocorticoids are frequently prescribed for the symptomatic management of inflammatory disorders such as RA, extended glucocorticoid exposure is the leading cause of osteoporosis and leaves patients at a high risk of fracture. The aim of this study is to evaluate the efficacy and safety of monthly oral minodronate for the treatment of osteop...

ea0032p97 | Bone and Osteoporosis | ECE2013

Change in bone mass in patients with established hyperthyroidism

Toti Florian , Ruci Dorina , Backa Teuta , Petrela Elizama

Objectives: To evaluate the presence and the degree of osteoporosis and osteopenia in a group of patients with established hyperthyroidism from at least 6 months.Material and methods: This study was based on a quantitative measurement of bone mineral density with and heel ultrasound densitometer (Type Pegassus). Each selected patient was recorded for the weight, height, BMI, age, and gender. No patient was previously treated for osteoporosis or osteopeni...

ea0032p98 | Bone and Osteoporosis | ECE2013

The follow-up in patients evaluated based on quantitative ultrasound: a prospective study

Carsote Mara , Radoi Valentin , Popescu Mihaela , Dusceac Roxana , Ene Cristina , Voicu Gabriela , Coculescu Mihail , Poiana Catalina

Introduction: The heel quantitative ultrasound (QUS) is useful tool in the assessment of fracture risk especially if cost issues are involved. It might be helpful in follow-up the patients who will not be treated with anti-osteoporotic drugs.Aim: To present the bone evaluation (DXA) after a period of time in patients who are initially assesed by both DXA and QUS.Material and patients: This is a prospective pilot study in a group of...

ea0032p99 | Bone and Osteoporosis | ECE2013

Prospective study of bone mineral density in girls treated with estroprogestagens for functional hypothalamic amenorrhea during late puberty in relation to the polymorphism of VDR (BsmI), ER (PvuII; Xba I), and COLIA1 genes

Sowinska-Przepiera Elzbieta , Andrysiak-Mamos Elzbieta , Jarzabek-Bielecka Grazyna , Syrenicz Justyna , Chelstowski Kornel , Syrenicz Anhelli

Introduction: The aim of this study was to verify if genetic factors influence the short- and long-term therapeutic responses to oestroprogestagen (OP) therapy, implemented in girls with functional hypothalamic amenorrhoea (FHA) in order to improve their bone mineral density (BMD).Material and methods: The study included 84 FHA girls who underwent a 4-year sequential OP therapy with 17-β oestradiol and didrogesterone. Changes in the lumbar spine BMD...

ea0032p100 | Bone and Osteoporosis | ECE2013

Vertebral fracture prevalence in postmenopausal women in relation to bone mineral density (BMD)

Novakovic-Paro Jovanka , Kovacev-Zavisic Branka , Mitrovic Milena , Tomic-Naglic Dragana , Medic-Stojanoska Milica , Bajkin Ivana , Icin Tijana , Popovic Djordje , Stokic Edita

Introduction: Epidemiological studies show that one half of vertebral fractures, which play an important role in estimation of future fracture risk, remain unrecognized.Aim: To establish vertebral fracture frequency in relation to bone mineral density in postmenopausal women.Methods: Study comprised 146 postmenopausal women. On the grounds of spine and hip DXA T-score based on WHO criteria subjects were divided to healthy,...

ea0032p101 | Bone and Osteoporosis | ECE2013

Vertebral fractures in women with postmenopausal osteoporosis with or without prior fragile fracture

Novakovic-Paro Jovanka , Kovacev-Zavisic Branka , Mitrovic Milena , Tomic-Naglic Dragana , Bajkin Ivana , Icin Tijana , Pejin Radoslav , Tesic Dragan , Benc Damir , Medic-Stojanoska Milica

Introduction: Vertebral fragile fracture is risk factor for future vertebral and hip fractures.Aim: To establish prevalence of vertebral fractures using lateral DXA scan of thoracic and lumbar spine in women with postmenopausal osteoporosis.Method: Study comprised 73 women with postmenopausal osteoporosis diagnosed using spine and hip DXA. Vertebral fractures were verified by lateral DXA scan vertebral morphometry of thoracic and l...

ea0032p102 | Bone and Osteoporosis | ECE2013

Effect of long-term valproate therapy on bone health parameters

Jyotsna V P , Singla Rajiv , Singh M B , Suma S V , Gupta Nandita

Introduction: Anti-epileptic drugs (AED) adversely affecting bone health. However, individual variations between different AEDs exist and not all AEDs are equally toxic to the bone. There is almost equipoise about the effect of valproate on bone.Methods: We conducted a cross-sectional study assessing bone mineral density with dual energy X-ray absorptiometry at the hip and lumbar spine in 33 outpatients receiving valproate for ≥1 year and 36 health...

ea0032p103 | Bone and Osteoporosis | ECE2013

Efficacy and safety of the anabolic therapies in severe osteoporosis: experience of a team of endocrinologists and spine surgeons

Mormando Marilda , Fusco Alessandra , Pola Enrico , Piacentini Serena , Nasto Luigi Aurelio , Colangelo Debora , Chiloiro Sabrina , Bianchi Antonio , Pontecorvi Alfredo , De Marinis Laura

Anabolic therapies represent a major advance in the management of severe osteoporosis. Parathyroid hormone (PTH) and human recombinant PTH peptide 1–34 (Teriparatide) demonstrated an increase in bone mineral density and a significant reduction in vertebral fractures in patients with osteoporosis when given for 18–24 months. The intermittent administration of PTH or teriparatide stimulates osteoblastic function, improves bone architecture and has an additional analges...

ea0032p104 | Bone and Osteoporosis | ECE2013

Vitamin D receptor, BsmI, FokI, ApaI, TaqI and estrogen receptor alpha, PvuII and XbaI, gene polymorphisms in women with osteoporosis

Vladoiu Susana , Oros Sabina , Manda Dana , Rosca Roxana , Ianas Olga

Objective: The aim of this study was to determine the frequencies of vitamin D receptor (VDR) Bsm1, Fok1, ApaI, TaqI and estrogen receptor α (ESR1) PvuII and XbaI polymorphisms in Romanian patients and to investigate their involvement in postmenopausal osteoporosis.Methods: The study was carried out on 82 postmenopausal women, aged over 60, divided into two groups: group 1-postmenopausal women with osteoporosis (34 subjects), group 2-postmenopausal ...

ea0032p105 | Bone and Osteoporosis | ECE2013

Possible benefits of PTH 1–84 therapy in pregnancy and lactation osteoporosis (PLO)

Pastore Renato

Introduction: Pregnancy and lactation associated osteoporosis (PLO) is a rare condition in which women typically present with fractures, often vertebral, in the third trimester of pregnancy or in the early postpartum period. Bone loss of 3–10% at the spine and hip are seen over 3–6 months of lactation. Bone loss is related to duration of lactation and amenorrhea and is not prevented by calcium supplementation.Methods: We studied a woma...

ea0032p106 | Bone and Osteoporosis | ECE2013

Influence of some traditional risk factors for osteoporosis on bone metabolism during substitution therapy of primary hypothyroidism

Pejin Radoslav , Mitrovic Milena , Novakovic-Paro Jovanka , Tomic-Naglic Dragana , Kovacev-Zavisic Branka , Tesic Dragan , Medic-Stojanoska Milica , Tomic Dusan , Bajkin Ivana , Todorovic-Djilas Ljiljana

Relation between thyroid hormones and bone metabolism markers in hyperthyroidism is well known. Earlier studies indicate possibility of bone metabolism acceleration during the excessive replacement therapy with L-thyroxine in hypothyroid patients especially in one with other risk factors for bone metabolism impairment. This study evaluated the effect of physiological L-thyroxine treatment on bone metabolism in patients with primary hypothyroidism....

ea0032p107 | Bone and Osteoporosis | ECE2013

Resolution of anaemia after curative parathyroidectomy in a patient with primary hyperparathyroidism

Anagnostis Panagiotis , Adamidou Fotini , Agapidou Alexandra , Vakalopoulou Sofia , Garipidou Vasilia , Kita Marina

Introduction: Despite the coexistence of secondary hyperparathyroidism with anaemia, hematological manifestations of primary hyperparathyroidism (PHPT) are rare.Case report: A 67-year-old Caucasian female was admitted to the Department of Internal Medicine due to normocytic anemia and hypercalcemia, diagnosed on occasion of muscle weakness and fatigability for 3 months.Her medication included: alendronate 70 mg/week, alphacalcidol ...

ea0032p108 | Bone and Osteoporosis | ECE2013

A case of 23 years old woman with primary hyperparathyroidism presenting with pathological fracture and brown tumors detected by scintigraphy

Canat M Masum , Ozturk Feyza Yener , Erol Selvinaz , Uludag Mehmet , Altuntas Yuksel

Introduction: Primary hyperparathyroidism (PHPT) occurs a peak incidence between ages 50 and 60 and the classical bone disease of PHPT or pathological fractures due to PHPT is rarely seen today. Furthermore brown tumor detected with Tc-99m MIBI scintigraphy exists in literature infrequently.Case: A 23 years old woman presented with left arm pain admitted in Department of Orthopaedics for pathological fracture in left humerus. As a result of investigation...

ea0032p109 | Bone and Osteoporosis | ECE2013

A patient osteogenesis imperfecta with osteoporosis

Ecemis Gulcin Cengiz , Kan Elif Kilic , Bahadir Cigdem Tura , Atmaca Aysegul , Atmaca Hulusi , Colak Ramis

Introduction: Osteogenesis imperfecta (OI) is a congenital, generalized connective tissue disorder characterized by severe osteoporosis and bone fragility. OI is most commonly caused by mutations in genes encoding the α-1 and α-2 chains of type I collagen or proteins involved in posttranslational modification of type I collagen. Although, no controlled studies are done, bisphosphonates are used for the treatment of OI. I.v. bisphosphonates are reported to be more eff...

ea0032p110 | Bone and Osteoporosis | ECE2013

Fear of illness and quality of life in Greek postmenopausal women with osteoporosis

Mintziori Gesthimani , Golias Vasileios , Triantafyllou Areti , Papadopoulou Stella-Leda , Tsiga Evangelia , Goulis Dimitrios G

Introduction: Fear of illness and quality of life have been proven to be affected in women with osteoporosis. Osteoporosis causes an increase in morbidity and mortality but the direct ways by which it affects fear of illness and quality of life are not yet known. The present study aims to assess the fear of illness and quality of life (QoL) as well as their correlation with bone density and age in a Greek rural population of postmenopausal women with osteoporosis.<p class=...